Keystone: TBI—Learning From Markers, Models, and Diseases
Injury to the brain, even what might be considered mild, can have devastating consequences on brain physiology...
ALL NEWS
472 RESULTS
Sort By:
- Most Recent
- Most Commented
Geneva: Biomarker News Morsels Amid Immunotherapy Review
Advances in therapy saw little sprigs of news pop up in talks that otherwise took stock of the current status of immunotherapy as one of the major new approaches...
Uppsala: Immunotherapy and Biomarkers Take Center Stage
In addition to immunotherapy, a meeting in Uppsala, Sweden, focused on recent progress in the development of novel disease biomarkers...
Translational Biomarkers in Alzheimer Disease Research, Part 3
This is part 3 of a 5-part series. See also <a href="/news/conference-coverage/translational-biomarkers-alzheimer-disease-research-part-1">part 1</a> and <a href="/news/conference-coverage/translational-biomarkers-alzheimer-disease-research-part-2">part 2</a>...
NIH Summit Sets Agenda for AD-Related Dementias
Among 20 focus areas, 47 research recommendations cover the gamut from basic science to health disparities.
Results from IDEAS Study Published
A majority of amyloid PET scans led physicians to change how they managed a patient’s disease. The effect on later outcomes is yet to be come.
New Money to Spur Tech Search for AD Biomarkers
Diagnostics Accelerator to fund projects that develop dementia biomarkers from patient data.
With Sudden Progress, Blood Aβ Rivals PET at Detecting Amyloid
At AAIC, competitors vied for advantage, and discussion moved swiftly to the issue of assay standardization.
TADPOLE Challenge: Winners Forecast AD Symptoms
Using different techniques, contestants vied for the best way to tell which ADNI participants would develop clinical, cognitive, or imaging signs of Alzheimer’s disease.
Can Researchers Detect Dementia With Lewy Bodies at the Prodromal Stage?
The field is searching for a combination of clinical features and biomarkers that will identify the disease in people with mild cognitive impairment.
Crenezumab Update: Baseline Data from Colombian Prevention Trial
At AAIC, researchers presented baseline data from an ongoing, five-year study asking whether the anti-Aβ antibody crenezumab can forestall cognitive decline in autosomal-dominant Alzheimer’s disease.
Why Bother With Round Robins on Blood Tests? Q&A with Kaj Blennow
What’s with all those head-to-head comparison studies of academic and commercial biomarker tests? Could we not just pick one that works, and be done?
Refining Models of Amyloid Accumulation in Alzheimer’s Disease
Clinical trial design could benefit from new estimates of how slowly amyloid accumulates and how best to detect it at various disease stages.
Pee P75: A Potential Biomarker of ALS Progression?
ALS patients eliminate more p75 neurotrophin receptor than do healthy controls. P75 urine levels rise as disease worsens.
Move Over Aβ, CSF P-Tau Tells Us There’s Plaque in the Brain
At AAIC, researchers touted phospho-tau species, especially p217 and p181. They tick up in CSF as an early response to amyloid accumulation.